186 related articles for article (PubMed ID: 37554366)
1. Cardiovascular changes in the NZB/W F1 mouse model of lupus nephritis.
Böhme R; Daniel C; Ferrazzi F; Angeloni M; Ekici AB; Winkler TH; Hilgers KF; Wellmann U; Voll RE; Amann K
Front Cardiovasc Med; 2023; 10():1182193. PubMed ID: 37554366
[TBL] [Abstract][Full Text] [Related]
2. HSPB5 suppresses renal inflammation and protects lupus-prone NZB/W F1 mice from severe renal damage.
Knapp J; Braunstein M; Berg SIT; Shirriff C
Arthritis Res Ther; 2022 Dec; 24(1):267. PubMed ID: 36510250
[TBL] [Abstract][Full Text] [Related]
3. The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice.
Sitrin J; Suto E; Wuster A; Eastham-Anderson J; Kim JM; Austin CD; Lee WP; Behrens TW
J Immunol; 2017 Aug; 199(4):1238-1249. PubMed ID: 28696253
[TBL] [Abstract][Full Text] [Related]
4. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel Poly (I:C)-induced murine model with accelerated lupus nephritis and examination of the therapeutic effects of mycophenolate mofetil and a cathepsin S inhibitor.
Kawato Y; Fukahori H; Nakamura K; Kubo K; Hiramitsu M; Kinugasa F; Morokata T
Eur J Pharmacol; 2023 Jan; 938():175440. PubMed ID: 36463947
[TBL] [Abstract][Full Text] [Related]
6. Similarity and difference between systemic lupus erythematosus and NZB/W F1 mice by multi-omics analysis.
Okuma K; Oku T; Sasaki C; Kitagori K; Mimori T; Aramori I; Hirayama Y; Yoshifuji H
Mod Rheumatol; 2024 Feb; 34(2):359-368. PubMed ID: 36869711
[TBL] [Abstract][Full Text] [Related]
7. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.
Moser K; Kalies K; Szyska M; Humrich JY; Amann K; Manz RA
Arthritis Rheum; 2012 Apr; 64(4):1237-46. PubMed ID: 22006377
[TBL] [Abstract][Full Text] [Related]
8. Pim-1 as a Therapeutic Target in Lupus Nephritis.
Fu R; Xia Y; Li M; Mao R; Guo C; Zhou M; Tan H; Liu M; Wang S; Yang N; Zhao J
Arthritis Rheumatol; 2019 Aug; 71(8):1308-1318. PubMed ID: 30791224
[TBL] [Abstract][Full Text] [Related]
9. Renal platelet-derived growth factor gene expression in NZB/W F1 mice with lupus and ddY mice with IgA nephropathy.
Nakamura T; Ebihara I; Nagaoka I; Tomino Y; Koide H
Clin Immunol Immunopathol; 1992 May; 63(2):173-81. PubMed ID: 1611719
[TBL] [Abstract][Full Text] [Related]
10. Function of the Th17/interleukin-17A immune response in murine lupus nephritis.
Schmidt T; Paust HJ; Krebs CF; Turner JE; Kaffke A; Bennstein SB; Koyro T; Peters A; Velden J; Hünemörder S; Haag F; Steinmetz OM; Mittrücker HW; Stahl RA; Panzer U
Arthritis Rheumatol; 2015 Feb; 67(2):475-87. PubMed ID: 25385550
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus.
Decker DA; Grant C; Oh L; Becker PM; Young D; Jordan S
Lupus; 2014 Jul; 23(8):802-12. PubMed ID: 24759631
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic inhibition of soluble epoxide hydrolase delays onset of nephritis and ameliorates kidney damage in NZB/W F1 mice.
Klocke J; Ulu A; Wu K; Rudolph B; Dragun D; Gollasch M; Schunck WH; Hammock BD; Riemekasten G; Enghard P
Sci Rep; 2019 Jun; 9(1):8993. PubMed ID: 31222024
[TBL] [Abstract][Full Text] [Related]
13. Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB/W F1 mice.
Nakamura T; Ebihara I; Fukui M; Osada S; Tomino Y; Masaki T; Goto K; Furuichi Y; Koide H
Ren Physiol Biochem; 1993; 16(5):233-43. PubMed ID: 7694336
[TBL] [Abstract][Full Text] [Related]
14. Effects of AS2819899, a novel selective PI3Kδ inhibitor, in a NZB/W F1 mouse lupus-like nephritis model.
Kaneko Y; Fukahori H; Yamagami K; Kawashima T; Ito M; Akamatsu M; Marui T; Kato K; Takahashi F; Morokata T
Int Immunopharmacol; 2020 Oct; 87():106764. PubMed ID: 32736191
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis.
Pohlmeyer CW; Shang C; Han P; Cui ZH; Jones RM; Clarke AS; Murray BP; Lopez DA; Newstrom DW; Inzunza MD; Matzkies FG; Currie KS; Di Paolo JA
BMC Rheumatol; 2021 Mar; 5(1):15. PubMed ID: 33781343
[TBL] [Abstract][Full Text] [Related]
16. Microarray-based analysis of renal complement components reveals a therapeutic target for lupus nephritis.
Liu T; Yang M; Xia Y; Jiang C; Li C; Jiang Z; Wang X
Arthritis Res Ther; 2021 Aug; 23(1):223. PubMed ID: 34433493
[TBL] [Abstract][Full Text] [Related]
17. Prominent renal expression of a murine leukemia retrovirus in experimental systemic lupus erythematosus.
Alexander JJ; Saxena AK; Bao L; Jacob A; Haas M; Quigg RJ
J Am Soc Nephrol; 2002 Dec; 13(12):2869-77. PubMed ID: 12444205
[TBL] [Abstract][Full Text] [Related]
18. Contribution of the gene linked to the T cell receptor beta chain gene complex of NZW mice to the autoimmunity of (NZB x NZW)F1 mice.
Hirose S; Tokushige K; Kinoshita K; Nozawa S; Saito J; Nishimura H; Shirai T
Eur J Immunol; 1991 Mar; 21(3):823-6. PubMed ID: 1826267
[TBL] [Abstract][Full Text] [Related]
19. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis.
Enghard P; Langnickel D; Riemekasten G
Scand J Rheumatol; 2006; 35(3):209-16. PubMed ID: 16766368
[TBL] [Abstract][Full Text] [Related]
20. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice.
Chen KJ; Zhang J; LaSala D; Basso J; Chun D; Zhou Y; McDonald PP; Perkins WR; Cipolla DC
Front Immunol; 2023; 14():1185727. PubMed ID: 37441081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
